The Supreme Court ruling allowing the Federal Trade Commission to legally challenge patent settlements can help save patients save millions in medication costs only if cheaper generic drugs reach pharmacy shelves, Alice Park writes. The verdict could push generics-makers to think twice and delay efforts to market their products, Park writes. "We are disappointed that the majority failed to provide clear and unambiguous guidance as to how patent settlements could be structured to avoid antitrust exposure short of litigating a patent dispute to the end," PhRMA General Counsel Mit Spears said in response to the ruling.

Full Story:

Related Summaries